Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733405 | 0.91 | TSHR (0.50) | KMT2AMAPTHSD17B10ACLYTSHR | |
| SCHEMBL30733423 | 0.83 | KCNN4 (0.47) | KMT2AACLYLMNAHTTNOTUM | |
| SCHEMBL25281852 | 0.82 | MEN1 (0.54) | KMT2AACLYLMNANOTUMNPY5R | |
| SCHEMBL29386556 | 0.82 | MEN1 (0.54) | KMT2AACLYLMNANOTUMNPY5R | |
| SCHEMBL30733401 | 0.80 | NOTUM (0.45) | ACLYNOTUMNPY5R | |
| SCHEMBL25276068 | 0.80 | KMT2A (0.43) | KMT2AACLYTSHRLMNAMAPK1 | |
| SCHEMBL26969734 | 0.78 | MMP2 (0.44) | KMT2AACLYHTTNOTUMNPY5R | |
| SCHEMBL26969764 | 0.77 | ACLY (0.41) | KMT2AACLYNOTUMNPY5R | |
| SCHEMBL25238614 | 0.77 | NOTUM (0.42) | MAPTACLYLMNANOTUMNPY5R | |
| SCHEMBL30733407 | 0.77 | AKR1B1 (0.47) | ACLYNOTUMNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | KMT2A 2892/4885MAPT 1167/4885HSD17B10 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.